Clinical characteristics of uveal melanoma in patients with germline BAP1 mutations

JAMA Ophthalmology

Volumn 133, Issue 8, 2015, Pages 881-887

  Gupta, Mrinali P ^a,b   Lane, Anne Marie ^a   DeAngelis, Margaret M ^a   Mayne, Katie ^a   Crabtree, Margaux ^a   Gragoudas, Evangelos S ^a   Kim, Ivana K ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BAP1 PROTEIN; MEMBRANE PROTEIN; UNCLASSIFIED DRUG; BAP1 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN THIOLESTERASE;

ADULT; ARTICLE; BLOOD SAMPLING; CANCER RISK; CANCER SIZE; CILIARY BODY; COHORT ANALYSIS; CONTROLLED STUDY; CUTANEOUS MELANOMA; EYE MELANOMA; FAMILY HISTORY; FEMALE; GENE SEQUENCE; GERMLINE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; METASTASIS; MIDDLE AGED; OPTIC NERVE; PHENOTYPE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEX DIFFERENCE; UNIVERSITY HOSPITAL; UVEA MELANOMA; VISUAL ACUITY; DNA SEQUENCE; GENETICS; MELANOMA; POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; UVEAL NEOPLASMS;

FEMALE; GERM-LINE MUTATION; HUMANS; MALE; MELANOMA; MIDDLE AGED; PHENOTYPE; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; SEQUENCE ANALYSIS, DNA; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN THIOLESTERASE; UVEAL NEOPLASMS; VISUAL ACUITY;

EID: 84939510430     PISSN: 21686165     EISSN: 21686173     Source Type: Journal    
DOI: 10.1001/jamaophthalmol.2015.1119     Document Type: Article

References (36)

1. Singh AD, Topham A. Incidence of uveal melanoma in the United States: 1973-1997. Ophthalmology. 2003;110(5):956-961.
2. Prescher G, Bornfeld N, Hirche H, Horsthemke B, Jöckel KH, Becher R. Prognostic implications of monosomy 3 in uveal melanoma. Lancet. 1996;347 (9010):1222-1225.
3. Sisley K, Rennie IG, Parsons MA, et al. Abnormalities of chromosomes 3 and 8 in posterior uveal melanoma correlate with prognosis. Genes Chromosomes Cancer. 1997;19(1):22-28.
4. Harbour JW, Onken MD, Roberson EDO, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science. 2010;330(6009):1410-1413.
5. Abdel-Rahman MH, Pilarski R, Cebulla CM, et al. Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J Med Genet. 2011;48(12):856-859.
6. Aoude LG, Vajdic CM, Kricker A, Armstrong B, Hayward NK. Prevalence of germline BAP1 mutation in a population-based sample of uveal melanoma cases. Pigment Cell Melanoma Res. 2013;26(2): 278-279.
7. Aoude LG, Wadt K, Bojesen A, et al. A BAP1 mutation in a Danish family predisposes to uveal melanoma and other cancers. PLoS One. 2013;8(8): e72144. doi:10.1371/journal.pone.0072144.
8. Höiom V, Edsgärd D, Helgadottir H, et al. Hereditary uveal melanoma: a report of a germline mutation in BAP1. Genes Chromosomes Cancer. 2013;52(4):378-384.
9. Maerker DA, Zeschnigk M, Nelles J, et al. BAP1 germline mutation in two first grade family members with uveal melanoma. Br J Ophthalmol. 2014;98(2):224-227.
10. Njauw CN, Kim I, Piris A, et al. Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families. PLoS One. 2012;7(4):e35295. doi:10.1371/journal.pone.0035295.
11. Cheung M, Talarchek J, Schindeler K, et al. Further evidence for germline BAP1 mutations predisposing to melanoma and malignant mesothelioma. Cancer Genet. 2013;206(5):206-210.
12. Pilarski R, Cebulla CM, Massengill JB, et al. Expanding the clinical phenotype of hereditary BAP1 cancer predisposition syndrome, reporting three new cases. Genes Chromosomes Cancer. 2014;53(2):177-182.
13. Wiesner T, Obenauf AC, Murali R, et al. Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet. 2011;43(10):1018-1021.
14. Sunyaev S, Ramensky V, Koch I, Lathe WIII, Kondrashov AS, Bork P. Prediction of deleterious human alleles. Hum Mol Genet. 2001;10(6):591-597.
15. Ng PC, Henikoff S. Predicting deleterious amino acid substitutions. Genome Res. 2001;11(5):863-874.
16. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc. 2009;4(7):1073-1081.
17. Holladay JT. Proper method for calculating average visual acuity. J Refract Surg. 1997;13(4): 388-391.
18. Gragoudas E, Li W, Goitein M, Lane AM, Munzenrider JE, Egan KM. Evidence-based estimates of outcome in patients irradiated for intraocular melanoma. Arch Ophthalmol. 2002;120 (12):1665-1671.
19. Kujala E, Mäkitie T, Kivelä T. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2003;44(11): 4651-4659.
20. Singh AD, Shields CL, Shields JA. Prognostic factors in uveal melanoma. Melanoma Res. 2001;11 (3):255-263.
21. Seddon JM, Albert DM, Lavin PT, Robinson N. A prognostic factor study of disease-free interval and survival following enucleation for uveal melanoma. Arch Ophthalmol. 1983;101(12): 1894-1899.
22. Shields CL, Shields JA, De Potter P, Cater J, Tardio D, Barrett J. Diffuse choroidal melanoma: clinical features predictive ofmetastasis. Arch Ophthalmol. 1996;114(8):956-963.
23. McLean IW, Foster WD, Zimmerman LE. Uveal melanoma: location, size, cell type, and enucleation as risk factors inmetastasis. Hum Pathol. 1982;13 (2):123-132.
24. Folberg R, Rummelt V, Parys-Van Ginderdeuren R, et al. The prognostic value of tumor blood vessel morphology in primary uveal melanoma. Ophthalmology. 1993;100(9):1389-1398.
25. Onken MD, Worley LA, Ehlers JP, Harbour JW. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res. 2004;64(20): 7205-7209.
26. Zuidervaart W, van der Velden PA, Hurks MH, et al. Gene expression profiling identifies tumour markers potentially playing a role in uveal melanoma development. Br J Cancer. 2003;89(10): 1914-1919.
27. Tschentscher F, Hüsing J, Hölter T, et al. Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities. Cancer Res. 2003;63(10):2578-2584.
28. Onken MD, Lin AY, Worley LA, Folberg R, Harbour JW. Association between microarray gene expression signature and extravascular matrix patterns in primary uveal melanomas. Am J Ophthalmol. 2005;140(4):748-749.
29. Scheuermann JC, de Ayala Alonso AG, Oktaba K, et al. Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB. Nature. 2010;465(7295):243-247.
30. Yu H, Pak H, Hammond-Martel I, et al. Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair. Proc Natl Acad Sci U S A. 2014;111(1):285-290.
31. Eletr ZM, Wilkinson KD. An emerging model for BAP1's role in regulating cell cycle progression. Cell Biochem Biophys. 2011;60(1-2):3-11.
32. Koopmans AE, Verdijk RM, Brouwer RWW, et al. Clinical significance of immunohistochemistry for detection of BAP1 mutations in uveal melanoma. Mod Pathol. 2014;27(10):1321-1330.
33. Griewank KG, van de Nes J, Schilling B, et al. Genetic and clinico-pathologic analysis of metastatic uveal melanoma. Mod Pathol. 2014;27 (2):175-183.
34. Shah AA, Bourne TD, Murali R. BAP1 protein loss by immunohistochemistry: a potentially useful tool for prognostic prediction in patients with uveal melanoma. Pathology. 2013;45(7):651-656.
35. Onken MD, Worley LA, Long MD, et al. Oncogenic mutations in GNAQ occur early in uveal melanoma. Invest Ophthalmol Vis Sci. 2008;49(12): 5230-5234.
36. Koopmans AE, Vaarwater J, Paridaens D, Naus NC, Kilic E, de Klein A; Rotterdam Ocular Melanoma Study Group. Patient survival in uveal melanoma is not affected by oncogenic mutations in GNAQ and GNA11. Br J Cancer. 2013;109(2): 493-496.